Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities
Abstract Objective To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities. Design and Methods This is a secondary analysis o...
Saved in:
| Published in | The journal of clinical endocrinology and metabolism Vol. 107; no. 9; pp. e3816 - e3823 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
US
Oxford University Press
01.09.2022
Endocrine Society |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-972X 1945-7197 1945-7197 |
| DOI | 10.1210/clinem/dgac339 |
Cover
| Abstract | Abstract
Objective
To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities.
Design and Methods
This is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor α (TNFα)-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs).
Results
The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P = 0.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P = 0.038) and 24% (P = 0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P = 0.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2 ± 4.3 vs 35.5 ± 2.8%, P = 0.59). The ability of HDL to inhibit the TNFα-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar in T2D patients and controls (-70.6 ± 16.5 vs -63.5 ± 18.7%, P = 0.14; and -62.1 ± 13.2 vs -54.7 ± 17.7%, P = 0.16, respectively).
Conclusion
Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients. |
|---|---|
| AbstractList | Objective: To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with mpaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities. Design and Methods: This is a secondary analysis of the Lira-NAFLD study, including 20T2D patients atTO and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor [alpha] (TNFa)-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs). Results: The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P = 0.00008). As expressed relative to apolipoprotein Al, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P= 0.038) and 24% (P = 0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41 % higher (P= 0.026) Cholesterol efflux capacity of apoB-depleted plasma was similar inT2D patients and controls (36.2 [+ or -] 4.3 vs 35.5 [+ or -] 2.8%, P = 0.59). The ability of HDL to inhibit theTNF[alpha]-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar inT2D patients and controls (-70.6 [+ or -] 16.5 vs-63.5 [+ or -] 18.7%, P= 0.14; and -62.1 [+ or -] 13.2 vs-54.7 [+ or -] 17.7%, P=0.16, respectively). Conclusion: Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved inT2D patients. Key Words: HDL, lipidomics, anti-inflammatory effect, cholesterol efflux, type 2 diabetes Abstract Objective To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities. Design and Methods This is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor α (TNFα)-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs). Results The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P = 0.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P = 0.038) and 24% (P = 0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P = 0.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2 ± 4.3 vs 35.5 ± 2.8%, P = 0.59). The ability of HDL to inhibit the TNFα-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar in T2D patients and controls (-70.6 ± 16.5 vs -63.5 ± 18.7%, P = 0.14; and -62.1 ± 13.2 vs -54.7 ± 17.7%, P = 0.16, respectively). Conclusion Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients. Abstract Objective To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities. Design and Methods This is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor α (TNFα)-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs). Results The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P = 0.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P = 0.038) and 24% (P = 0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P = 0.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2 ± 4.3 vs 35.5 ± 2.8%, P = 0.59). The ability of HDL to inhibit the TNFα-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar in T2D patients and controls (-70.6 ± 16.5 vs -63.5 ± 18.7%, P = 0.14; and -62.1 ± 13.2 vs -54.7 ± 17.7%, P = 0.16, respectively). Conclusion Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients. To assess whether, in type 2 diabetic (T2D) patients, lipidomic abnormalities in high density lipoproteins (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, two pro-atherogenic abnormalities. This is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the TNFα-induced expression of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intercellular Cell Adhesion Molecule-1 (ICAM-1) on Human Vascular Endothelial Cells (HUVEC). The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared to controls (-46%, P=0.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides were respectively 27% (P=0.038) and 24% (P=0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P=0.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2±4.3 vs 35.5±2.8%, P=0.59). The ability of HDL to inhibit the TNFα-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVEC was similar in T2D patients and controls (-70.6±16.5 vs -63.5±18.7%, P=0.14 and -62.1±13.2 vs -54.7±17.7%, P=0.16, respectively). Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients. Objective: To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities. Design and Methods: This is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor [alpha] (TNF[alpha])-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs). Results: The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P = 0.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P = 0.038) and 24% (P = 0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P = 0.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2 [+ or -] 4.3 vs 35.5 [+ or -] 2.8%, P = 0.59). The ability of HDL to inhibit the TNF[alpha]-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar in T2D patients and controls (-70.6 [+ or -] 16.5 vs -63.5 [+ or -] 18.7%, P = 0.14; and -62.1 [+ or -] 13.2 vs -54.7 [+ or -] 17.7%, P = 0.16, respectively). Conclusion: Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients. Key Words: HDL, lipidomics, anti-inflammatory effect, cholesterol efflux, type 2 diabetes Objective To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities. Design and Methods This is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor α (TNFα)-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs). Results The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P = 0.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P = 0.038) and 24% (P = 0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P = 0.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2 ± 4.3 vs 35.5 ± 2.8%, P = 0.59). The ability of HDL to inhibit the TNFα-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar in T2D patients and controls (-70.6 ± 16.5 vs -63.5 ± 18.7%, P = 0.14; and -62.1 ± 13.2 vs -54.7 ± 17.7%, P = 0.16, respectively). Conclusion Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients. To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities.OBJECTIVETo assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities.This is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor α (TNFα)-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs).DESIGN AND METHODSThis is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor α (TNFα)-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs).The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P = 0.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P = 0.038) and 24% (P = 0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P = 0.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2 ± 4.3 vs 35.5 ± 2.8%, P = 0.59). The ability of HDL to inhibit the TNFα-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar in T2D patients and controls (-70.6 ± 16.5 vs -63.5 ± 18.7%, P = 0.14; and -62.1 ± 13.2 vs -54.7 ± 17.7%, P = 0.16, respectively).RESULTSThe cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P = 0.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P = 0.038) and 24% (P = 0.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P = 0.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2 ± 4.3 vs 35.5 ± 2.8%, P = 0.59). The ability of HDL to inhibit the TNFα-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar in T2D patients and controls (-70.6 ± 16.5 vs -63.5 ± 18.7%, P = 0.14; and -62.1 ± 13.2 vs -54.7 ± 17.7%, P = 0.16, respectively).Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients.CONCLUSIONDespite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients. |
| Audience | Academic |
| Author | Bouillet, Benjamin Denimal, Damien Benanaya, Sara Pais de Barros, Jean-Paul Le Goff, Wilfried Simoneau, Isabelle Duvillard, Laurence Monier, Serge Vergès, Bruno |
| Author_xml | – sequence: 1 givenname: Damien surname: Denimal fullname: Denimal, Damien – sequence: 2 givenname: Sara surname: Benanaya fullname: Benanaya, Sara – sequence: 3 givenname: Serge surname: Monier fullname: Monier, Serge – sequence: 4 givenname: Isabelle surname: Simoneau fullname: Simoneau, Isabelle – sequence: 5 givenname: Jean-Paul surname: Pais de Barros fullname: Pais de Barros, Jean-Paul – sequence: 6 givenname: Wilfried orcidid: 0000-0002-7611-9644 surname: Le Goff fullname: Le Goff, Wilfried – sequence: 7 givenname: Benjamin orcidid: 0000-0002-4317-6714 surname: Bouillet fullname: Bouillet, Benjamin – sequence: 8 givenname: Bruno surname: Vergès fullname: Vergès, Bruno – sequence: 9 givenname: Laurence orcidid: 0000-0001-9320-793X surname: Duvillard fullname: Duvillard, Laurence email: laurence.duvillard@chu-dijon.fr |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35647758$$D View this record in MEDLINE/PubMed https://hal.science/hal-03946889$$DView record in HAL |
| BookMark | eNqNUstuEzEUHaEimha2LJElNrCY1s-xvUGKkkIqRbApEjvLM2Mnrjz2dB4V-XucJqQ0AhV5Yen6PKxzz1l2EmIwWfYWwQuEEbysvAumuaxXuiJEvsgmSFKWcyT5STaBEKNccvzjNDvr-1sIEaWMvMpOCSso50xMsruvsWu0B4v5EszW0Zt-MF304MpaP_4EOtRgGgaXXwfrddPoIXYbMNOtrtzgTA9cADeb1gAM5k6XZkijuelbNxiwdK2rY-MqMC3Dg8sD5XX20mrfmzf7-zz7_vnqZrbIl9--XM-my7xiAg65pVgYpIVlJaOQSYw45yWThmPMtGW6oKjAZV2wupLSVkYQZo3AjDIDa1KS8-zTTrcdy8bUlQlDp71qO9fobqOidurpS3BrtYr3ShLBCymTwMedwPqItpgu1XYGiaSFEPIeJeyHvVkX78YUompcXxnvdTBx7BUuOCZIEE4S9P0R9DaOXUhRKIIKyhDjRD6iVtob5YKN6Y_VVlRNUxCSMQLpcygmOEE8oS7-gkqnNmk7qU_WpfkT2f8lHBze_Zn1Ia3fPXtUrLrY952xBwiCaltktSuy2hc5EegRIRVODy5ud-X8v2n7ncWxfc7iF_OWBTE |
| CitedBy_id | crossref_primary_10_3390_metabo13020253 crossref_primary_10_1186_s12933_025_02624_9 crossref_primary_10_1002_ansa_202300009 crossref_primary_10_1016_j_cegh_2024_101811 crossref_primary_10_1007_s13300_023_01491_5 crossref_primary_10_3390_ijms242317090 crossref_primary_10_3389_fendo_2022_993193 crossref_primary_10_1016_j_aopr_2025_03_003 crossref_primary_10_3390_antiox13010057 crossref_primary_10_3390_ijms25158285 crossref_primary_10_1186_s12933_023_01909_1 crossref_primary_10_26641_2307_0404_2023_1_276010 crossref_primary_10_4239_wjd_v14_i3_159 crossref_primary_10_3390_metabo12080683 crossref_primary_10_1111_jgh_16760 crossref_primary_10_1002_bmc_70058 crossref_primary_10_1111_jdi_14172 |
| Cites_doi | 10.3390/ijms20030732 10.1161/CIRCULATIONAHA.120.050808 10.1016/j.atherosclerosis.2017.05.031 10.1096/fj.201801245R 10.1186/s12933-021-01260-3 10.1186/s12933-017-0613-8 10.1016/j.atherosclerosis.2008.07.047 10.2337/db12-0686 10.1016/j.bbalip.2013.07.009 10.1161/ATVBAHA.120.315648 10.1194/jlr.M300231-JLR200 10.2337/db11-0378 10.1016/j.metabol.2014.03.001 10.1161/ATVBAHA.109.184663 10.1161/ATVBAHA.109.194548 10.1194/jlr.M500263-JLR200 10.1210/jc.2014-2979 10.1186/1475-2840-12-27 10.1016/j.diabet.2021.101284 10.1038/srep27367 10.1139/o59-099 10.1161/ATVBAHA.119.312645 10.1007/s00125-012-2570-9 10.1161/01.ATV.17.11.2685 10.1161/ATVBAHA.116.307385 10.1056/NEJMoa1409065 10.1161/CIRCRESAHA.111.300104 10.1007/s00125-015-3525-8 10.1016/j.cellsig.2005.07.011 10.1161/CIRCRESAHA.116.305485 10.1194/jlr.M060285 10.1161/ATVBAHA.115.305504 10.1007/s00125-006-0574-z 10.1016/j.pharmthera.2015.10.010 10.1074/jbc.M605823200 10.1016/j.atherosclerosis.2015.12.042 10.1194/jlr.R036095 10.1021/bi992902m 10.1016/j.ymeth.2006.05.004 10.1074/jbc.M008725200 10.1161/ATVBAHA.109.199158 10.1016/S0022-2275(20)33375-7 10.1161/ATVBAHA.117.309287 10.1016/j.tem.2014.05.005 10.1016/j.bbalip.2015.05.007 10.1161/01.ATV.18.9.1450 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. 2022 The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. COPYRIGHT 2022 Oxford University Press Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. – notice: COPYRIGHT 2022 Oxford University Press – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | TOX AAYXX CITATION NPM 7QP 7T5 7TM H94 K9. 7X8 1XC 5PM |
| DOI | 10.1210/clinem/dgac339 |
| DatabaseName | Oxford Journals Open Access Collection CrossRef PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Hyper Article en Ligne (HAL) PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | PubMed AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access (Activated by CARLI) url: https://academic.oup.com/journals/ sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1945-7197 |
| EndPage | e3823 |
| ExternalDocumentID | PMC9387699 oai_HAL_hal_03946889v1 A777955304 A777587317 35647758 10_1210_clinem_dgac339 10.1210/clinem/dgac339 |
| Genre | Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GrantInformation_xml | – fundername: ; – fundername: ; grantid: ANR-11-LABX-0021 |
| GroupedDBID | --- -~X .55 .GJ .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 3O- 3V. 4.4 48X 53G 5GY 5RS 5YH 7X7 88E 8F7 8FI 8FJ AABZA AACZT AAIMJ AAJQQ AAKAS AAPGJ AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYJJ ABBLC ABDFA ABDPE ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABUWG ABVGC ABWST ABXVV ACFRR ACGFO ACGFS ACPRK ACUTJ ACYHN ACZBC ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK ADZCM AELWJ AEMDU AENEX AENZO AERZD AETBJ AEWNT AFCHL AFFNX AFFQV AFFZL AFGWE AFKRA AFOFC AFRAH AFXAL AFYAG AGINJ AGKRT AGMDO AGQXC AGUTN AHMBA AHMMS AI. AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT APJGH AQDSO AQKUS ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BSWAC BTRTY BVXVI C45 CCPQU CDBKE CS3 D-I DAKXR DIK E3Z EBS EIHJH EJD EMOBN ENERS F5P FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC GX1 H13 HMCUK HVGLF HZ~ H~9 IAO IHR INH ITC J5H KBUDW KOP KQ8 KSI KSN L7B M1P M5~ MBLQV MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G PQQKQ PROAC PSQYO REU ROX ROZ TEORI TJX TLC TMA TOX TR2 TWZ UKHRP VH1 VVN W8F WHG WOQ X52 X7M YBU YFH YHG YOC YSK ZGI ZXP ZY1 ~02 ~H1 AAYXX ABXZS ADNBA AEMQT AEOTA AGORE AHGBF AJBYB ALXQX CITATION NU- NPM 7QP 7T5 7TM AEHZK H94 K9. 7X8 1XC 5PM |
| ID | FETCH-LOGICAL-c580t-f428e1a8f5b5405921777b59e7225af5a64162bd65dc99fce835fe82545e0d3b3 |
| ISSN | 0021-972X 1945-7197 |
| IngestDate | Thu Aug 21 18:28:06 EDT 2025 Fri Sep 12 12:41:38 EDT 2025 Sat Sep 27 18:17:27 EDT 2025 Fri Sep 19 20:54:34 EDT 2025 Tue Jun 17 22:25:08 EDT 2025 Tue Jun 17 22:23:57 EDT 2025 Tue Jun 10 21:16:08 EDT 2025 Tue Jun 10 21:20:20 EDT 2025 Wed Feb 19 02:25:41 EST 2025 Tue Jul 01 01:11:07 EDT 2025 Thu Apr 24 23:03:44 EDT 2025 Fri Feb 07 10:35:43 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | HDL type 2 diabetes anti-inflammatory effect cholesterol efflux lipidomics |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://creativecommons.org/licenses/by-nc-nd/4.0 The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c580t-f428e1a8f5b5405921777b59e7225af5a64162bd65dc99fce835fe82545e0d3b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-7611-9644 0000-0002-4317-6714 0000-0001-9320-793X |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9387699 |
| PMID | 35647758 |
| PQID | 3164515739 |
| PQPubID | 2046206 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9387699 hal_primary_oai_HAL_hal_03946889v1 proquest_miscellaneous_2672318373 proquest_journals_3164515739 gale_infotracmisc_A777955304 gale_infotracmisc_A777587317 gale_infotracacademiconefile_A777955304 gale_infotracacademiconefile_A777587317 pubmed_primary_35647758 crossref_primary_10_1210_clinem_dgac339 crossref_citationtrail_10_1210_clinem_dgac339 oup_primary_10_1210_clinem_dgac339 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-09-01 |
| PublicationDateYYYYMMDD | 2022-09-01 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: United States – name: Washington |
| PublicationTitle | The journal of clinical endocrinology and metabolism |
| PublicationTitleAlternate | J Clin Endocrinol Metab |
| PublicationYear | 2022 |
| Publisher | Oxford University Press Endocrine Society |
| Publisher_xml | – name: Oxford University Press – name: Endocrine Society |
| References | Curtiss (2022081816081466500_CIT0010) 2000; 39 Bligh (2022081816081466500_CIT0028) 1959; 37 Keul (2022081816081466500_CIT0036) 2019; 33 Kimura (2022081816081466500_CIT0006) 2006; 281 Martin (2022081816081466500_CIT0027) 2014; 25 Ståhlman (2022081816081466500_CIT0002) 2013; 1831 Denimal (2022081816081466500_CIT0031) 2016; 246 Ebtehaj (2022081816081466500_CIT0022) 2017; 16 Apro (2022081816081466500_CIT0020) 2016; 36 Petit (2022081816081466500_CIT0024) 2017; 102 Baker (2022081816081466500_CIT0038) 1999; 40 Subbaiah (2022081816081466500_CIT0048) 2005; 46 Shiu (2022081816081466500_CIT0019) 2017; 263 Morgantini (2022081816081466500_CIT0021) 2011; 60 Kontush (2022081816081466500_CIT0012) 2013; 54 Tong (2022081816081466500_CIT0040) 2013; 12 Darabi (2022081816081466500_CIT0011) 2016; 157 Bielawski (2022081816081466500_CIT0029) 2006; 39 Patel (2022081816081466500_CIT0037) 2009; 204 Dullaart (2022081816081466500_CIT0016) 2019; 20 Agarwala (2022081816081466500_CIT0045) 2015; 35 Ebtehaj (2022081816081466500_CIT0003) 2019; 39 Fournier (2022081816081466500_CIT0046) 1997; 17 Low (2022081816081466500_CIT0017) 2012; 55 de la Llera-Moya (2022081816081466500_CIT0043) 2010; 30 Vergès (2022081816081466500_CIT0001) 2015; 58 Vergès (2022081816081466500_CIT0025) 2022; 48 Rached (2022081816081466500_CIT0014) 2015; 1851 Sang (2022081816081466500_CIT0023) 2015; 100 Yubero-Serrano (2022081816081466500_CIT0042) 2021; 20 Jia (2022081816081466500_CIT0005) 2021; 143 Boon (2022081816081466500_CIT0041) 2013; 62 Yassine (2022081816081466500_CIT0018) 2014; 63 McGrath (2022081816081466500_CIT0008) 2009; 29 Denimal (2022081816081466500_CIT0026) 2017; 37 Rohatgi (2022081816081466500_CIT0004) 2014; 371 Kimura (2022081816081466500_CIT0007) 2006; 18 Duvillard (2022081816081466500_CIT0030) Schwendeman (2022081816081466500_CIT0013) 2015; 56 Ashby (2022081816081466500_CIT0032) 1998; 18 Du (2022081816081466500_CIT0033) 2015; 116 Nobecourt (2022081816081466500_CIT0009) 2007; 50 Larrede (2022081816081466500_CIT0034) 2009; 29 Annema (2022081816081466500_CIT0015) 2016; 6 Greene (2022081816081466500_CIT0039) 2001; 276 Wu (2022081816081466500_CIT0035) 2013; 112 Yancey (2022081816081466500_CIT0047) 2004; 45 El-Ghazali (2022081816081466500_CIT0044) 2021; 41 |
| References_xml | – volume: 20 start-page: 732 issue: 3 year: 2019 ident: 2022081816081466500_CIT0016 article-title: Antibodies against the C-terminus of ApoA-1 are inversely associated with cholesterol efflux capacity and HDL Metabolism in subjects with and without type 2 diabetes mellitus publication-title: Int J Mol Sci. doi: 10.3390/ijms20030732 – volume: 143 start-page: 1935 issue: 20 year: 2021 ident: 2022081816081466500_CIT0005 article-title: High-density lipoprotein anti-inflammatory capacity and incident cardiovascular events publication-title: Circulation. doi: 10.1161/CIRCULATIONAHA.120.050808 – volume: 263 start-page: 24 year: 2017 ident: 2022081816081466500_CIT0019 article-title: Pre-β1 HDL in type 2 diabetes mellitus publication-title: Atherosclerosis. doi: 10.1016/j.atherosclerosis.2017.05.031 – volume: 33 start-page: 1482 issue: 1 year: 2019 ident: 2022081816081466500_CIT0036 article-title: Potent anti-inflammatory properties of HDL in vascular smooth muscle cells mediated by HDL-S1P and their impairment in coronary artery disease due to lower HDL-S1P: a new aspect of HDL dysfunction and its therapy publication-title: FASEB J. doi: 10.1096/fj.201801245R – volume: 20 start-page: 72 issue: 1 year: 2021 ident: 2022081816081466500_CIT0042 article-title: Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study publication-title: Cardiovasc Diabetol. doi: 10.1186/s12933-021-01260-3 – volume: 16 start-page: 132 issue: 1 year: 2017 ident: 2022081816081466500_CIT0022 article-title: The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation publication-title: Cardiovasc Diabetol. doi: 10.1186/s12933-017-0613-8 – volume: 204 start-page: 424 issue: 2 year: 2009 ident: 2022081816081466500_CIT0037 article-title: Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins publication-title: Atherosclerosis. doi: 10.1016/j.atherosclerosis.2008.07.047 – volume: 62 start-page: 401 issue: 2 year: 2013 ident: 2022081816081466500_CIT0041 article-title: Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance publication-title: Diabetes. doi: 10.2337/db12-0686 – volume: 1831 start-page: 1609 issue: 11 year: 2013 ident: 2022081816081466500_CIT0002 article-title: Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles publication-title: Biochim Biophys Acta. doi: 10.1016/j.bbalip.2013.07.009 – volume: 41 start-page: 2588 issue: 10 year: 2021 ident: 2022081816081466500_CIT0044 article-title: Molecular patterns of extreme and persistent cholesterol efflux capacity publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.120.315648 – volume: 45 start-page: 337 issue: 2 year: 2004 ident: 2022081816081466500_CIT0047 article-title: In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux publication-title: J Lipid Res. doi: 10.1194/jlr.M300231-JLR200 – volume: 60 start-page: 2617 issue: 10 year: 2011 ident: 2022081816081466500_CIT0021 article-title: Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes publication-title: Diabetes. doi: 10.2337/db11-0378 – volume: 63 start-page: 727 issue: 5 year: 2014 ident: 2022081816081466500_CIT0018 article-title: Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes publication-title: Metabolism. doi: 10.1016/j.metabol.2014.03.001 – volume: 29 start-page: 877 issue: 6 year: 2009 ident: 2022081816081466500_CIT0008 article-title: Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.109.184663 – volume: 29 start-page: 1930 issue: 11 year: 2009 ident: 2022081816081466500_CIT0034 article-title: Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.109.194548 – volume: 46 start-page: 2699 issue: 12 year: 2005 ident: 2022081816081466500_CIT0048 article-title: Regulation of the selective uptake of cholesteryl esters from high density lipoproteins by sphingomyelin publication-title: J Lipid Res. doi: 10.1194/jlr.M500263-JLR200 – volume: 100 start-page: 870 issue: 3 year: 2015 ident: 2022081816081466500_CIT0023 article-title: Walk-run training improves the anti-inflammation properties of high-density lipoprotein in patients with metabolic syndrome publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2014-2979 – volume: 12 start-page: 27 year: 2013 ident: 2022081816081466500_CIT0040 article-title: High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate publication-title: Cardiovasc Diabetol. doi: 10.1186/1475-2840-12-27 – volume: 48 start-page: 101284 issue: 2 year: 2022 ident: 2022081816081466500_CIT0025 article-title: Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins publication-title: Diabetes Metab. doi: 10.1016/j.diabet.2021.101284 – volume: 6 start-page: 27367 year: 2016 ident: 2022081816081466500_CIT0015 article-title: Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study publication-title: Sci Rep. doi: 10.1038/srep27367 – volume: 37 start-page: 911 issue: 8 year: 1959 ident: 2022081816081466500_CIT0028 article-title: A rapid method of total lipid extraction and purification publication-title: Can J Biochem Physiol. doi: 10.1139/o59-099 – volume: 39 start-page: 1874 issue: 9 year: 2019 ident: 2022081816081466500_CIT0003 article-title: HDL (high-density lipoprotein) cholesterol efflux capacity is associated with incident cardiovascular disease in the general population publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.119.312645 – volume: 55 start-page: 2513 issue: 9 year: 2012 ident: 2022081816081466500_CIT0017 article-title: Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models publication-title: Diabetologia. doi: 10.1007/s00125-012-2570-9 – volume: 17 start-page: 2685 issue: 11 year: 1997 ident: 2022081816081466500_CIT0046 article-title: HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/01.ATV.17.11.2685 – volume: 36 start-page: 787 issue: 5 year: 2016 ident: 2022081816081466500_CIT0020 article-title: Impaired cholesterol efflux capacity of high-density lipoprotein isolated from interstitial fluid in type 2 diabetes mellitus-brief report publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.116.307385 – volume: 371 start-page: 2383 issue: 25 year: 2014 ident: 2022081816081466500_CIT0004 article-title: HDL cholesterol efflux capacity and incident cardiovascular events publication-title: N Engl J Med. doi: 10.1056/NEJMoa1409065 – volume: 112 start-page: 278 issue: 2 year: 2013 ident: 2022081816081466500_CIT0035 article-title: High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-Δ24 reductase expression and inducing heme oxygenase-1 publication-title: Circ Res. doi: 10.1161/CIRCRESAHA.111.300104 – volume: 58 start-page: 886 issue: 5 year: 2015 ident: 2022081816081466500_CIT0001 article-title: Pathophysiology of diabetic dyslipidaemia: where are we? publication-title: Diabetologia. doi: 10.1007/s00125-015-3525-8 – volume: 18 start-page: 841 issue: 6 year: 2006 ident: 2022081816081466500_CIT0007 article-title: Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells publication-title: Cell Signal. doi: 10.1016/j.cellsig.2005.07.011 – volume: 116 start-page: 1133 issue: 7 year: 2015 ident: 2022081816081466500_CIT0033 article-title: HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export publication-title: Circ Res. doi: 10.1161/CIRCRESAHA.116.305485 – volume: 56 start-page: 1727 issue: 9 year: 2015 ident: 2022081816081466500_CIT0013 article-title: The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties publication-title: J Lipid Res. doi: 10.1194/jlr.M060285 – volume: 35 start-page: 1515 issue: 6 year: 2015 ident: 2022081816081466500_CIT0045 article-title: HDL phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL-C and coronary disease publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.115.305504 – volume: 50 start-page: 643 issue: 3 year: 2007 ident: 2022081816081466500_CIT0009 article-title: The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase publication-title: Diabetologia. doi: 10.1007/s00125-006-0574-z – volume: 157 start-page: 28 year: 2016 ident: 2022081816081466500_CIT0011 article-title: Therapeutic applications of reconstituted HDL: when structure meets function publication-title: Pharmacol Ther. doi: 10.1016/j.pharmthera.2015.10.010 – volume: 281 start-page: 37457 issue: 49 year: 2006 ident: 2022081816081466500_CIT0006 article-title: Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells publication-title: J Biol Chem. doi: 10.1074/jbc.M605823200 – volume: 246 start-page: 106 year: 2016 ident: 2022081816081466500_CIT0031 article-title: Major changes in the sphingophospholipidome of HDL in non-diabetic patients with metabolic syndrome publication-title: Atherosclerosis. doi: 10.1016/j.atherosclerosis.2015.12.042 – ident: 2022081816081466500_CIT0030 – volume: 54 start-page: 2950 issue: 11 year: 2013 ident: 2022081816081466500_CIT0012 article-title: Unraveling the complexities of the HDL lipidome publication-title: J Lipid Res. doi: 10.1194/jlr.R036095 – volume: 102 start-page: 407 issue: 2 year: 2017 ident: 2022081816081466500_CIT0024 article-title: Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study publication-title: J Clin Endocrinol Metab. – volume: 39 start-page: 5712 issue: 19 year: 2000 ident: 2022081816081466500_CIT0010 article-title: The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study publication-title: Biochemistry. doi: 10.1021/bi992902m – volume: 39 start-page: 82 issue: 2 year: 2006 ident: 2022081816081466500_CIT0029 article-title: Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry publication-title: Methods. doi: 10.1016/j.ymeth.2006.05.004 – volume: 276 start-page: 4804 issue: 7 year: 2001 ident: 2022081816081466500_CIT0039 article-title: Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI) publication-title: J Biol Chem. doi: 10.1074/jbc.M008725200 – volume: 30 start-page: 796 issue: 4 year: 2010 ident: 2022081816081466500_CIT0043 article-title: The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.109.199158 – volume: 40 start-page: 345 issue: 2 year: 1999 ident: 2022081816081466500_CIT0038 article-title: Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells publication-title: J Lipid Res. doi: 10.1016/S0022-2275(20)33375-7 – volume: 37 start-page: 804 issue: 5 year: 2017 ident: 2022081816081466500_CIT0026 article-title: Impairment of the ability of HDL from patients with metabolic syndrome but without diabetes mellitus to activate eNOS: correction by S1P enrichment publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.117.309287 – volume: 25 start-page: 329 issue: 7 year: 2014 ident: 2022081816081466500_CIT0027 article-title: High-density lipoprotein subfractions: current views and clinical practice applications publication-title: Trends Endocrinol Metab. doi: 10.1016/j.tem.2014.05.005 – volume: 1851 start-page: 1254 issue: 9 year: 2015 ident: 2022081816081466500_CIT0014 article-title: Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A publication-title: Biochim Biophys Acta. doi: 10.1016/j.bbalip.2015.05.007 – volume: 18 start-page: 1450 year: 1998 ident: 2022081816081466500_CIT0032 article-title: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/01.ATV.18.9.1450 |
| SSID | ssj0014453 |
| Score | 2.5067618 |
| Snippet | Abstract
Objective
To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired... To assess whether, in type 2 diabetic (T2D) patients, lipidomic abnormalities in high density lipoproteins (HDL) are associated with impaired cholesterol... Objective: To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired... Objective: To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with mpaired... Objective To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired... To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux... Abstract Objective To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired... |
| SourceID | pubmedcentral hal proquest gale pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e3816 |
| SubjectTerms | Analysis Anti-inflammatory drugs Blood cholesterol Cell adhesion & migration Cell adhesion molecules Ceramides Cholesterol Chromatography Diabetes Diabetes mellitus (non-insulin dependent) Endothelial cells Ethylenediaminetetraacetic acid High density lipoprotein Inflammation Intercellular adhesion molecule 1 Life Sciences Lipids Liquid chromatography Macrophages Mass spectrometry Mass spectroscopy Medical research Medicine, Experimental Online Only Phosphates Phosphatidylethanolamine Phospholipids Sphingolipids Sphingosine Sphingosine 1-phosphate Tumor necrosis factor Tumor necrosis factor-α Type 2 diabetes Vascular cell adhesion molecule 1 |
| Title | Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35647758 https://www.proquest.com/docview/3164515739 https://www.proquest.com/docview/2672318373 https://hal.science/hal-03946889 https://pubmed.ncbi.nlm.nih.gov/PMC9387699 |
| Volume | 107 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELa6i4S4IN4UCjIIiUMVyMtxfCwtqy7s7qkr7S1yEoet1LpAUwT8P_4XM7GTJktXFC5RFT_iZL6OZ8bzIOSVL_wUmKPnFDLwnTDnypHCzZxAsDTiaQ6LR4P-6Vk0PQ8_XLCLXu9Xy2tpU6Zvsp8740r-h6pwD-iKUbL_QNlmUrgBv4G-cAUKw3UvGp-hwLkYTicnwzHWucWkB6sFVktebL5XxwIjXc6dY10A3ZfmPH0Mu2NWpVFFU8fMWGAntQV2gifvpRpiSescA5aHo1RXT6mGtEVZBFgr70QTYql0vgJWpLfJnZaqBKgt6mSFKDYrPV9WpQYAdsv5NhztndJSyx-yNlY3eADWY0uEYbhoYxcCpGklNxWnW0s8RFFtOwaowLWj1jauwHMEr4qrw85k2LEImcM948Hb8GtTJtcCU7S4r8JT0NZWrvCQc-c-AYouEBe_jIK_3VH-SWaBSarUTcl9ZatsHBhRdYI5EjNDYscfkBs-jyIspDE5_tgcZoWhTYZqX9DmDsXgKTP-rR3fkY2shHBwiQ66neDLlg501ZW3JRvN7pDbVqmhI4PQu6Sn9D1y89S6bdwnXwxQKQCVtoBKDVApYIT-AVS6BSqda4pApT6tgUotUGkDVNoB6gNyfvR-Np46ttaHk7HYLZ0C1GDlybhgKeoQAjRlzlMmFIcNRxZMRqA5-GkesTwTosgUaA6FQvMGU24epMFDcqgBcY8JxZSIMXPDNJA8zFghisgNszhS0lVMpG6fOPVXTjKbCB_rsSyS3VTtk9dN_88mBcz1PZFoCUINZsykDXGBdWGWtWQE78RiDiL7Pj0FVvQK-2TQ6QncP-tMdE1zPfol4KdZNuaSn45OErznBiKM4lh886ATwOuv7zao0ZdY5rJOAi8KQSHi2PyiacY1oOumVqvNOvEj7qPgwIM-eWTA2jwqYBgHz-I-4R0YdxbcbdHzyyoJvghAjhPiyd7EeUpubdnOgByWXzfqGSgUZfq8-rv-BrAeJ3o |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Normal+HDL+Cholesterol+Efflux+and+Anti-Inflammatory+Capacities+in+Type+2+Diabetes+Despite+Lipidomic+Abnormalities&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Denimal%2C+Damien&rft.au=Benanaya%2C+Sara&rft.au=Monier%2C+Serge&rft.au=Simoneau%2C+Isabelle&rft.date=2022-09-01&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=107&rft.issue=9&rft.spage=e3816&rft.epage=e3823&rft_id=info:doi/10.1210%2Fclinem%2Fdgac339&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_clinem_dgac339 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |